Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro

[1]  W. Helfrich,et al.  Antibody-based fusion proteins to target death receptors in cancer. , 2013, Cancer letters.

[2]  L. Pardo,et al.  Tumor cell-selective apoptosis induction through targeting of KV10.1 via bifunctional TRAIL antibody , 2011, Molecular Cancer.

[3]  A. van Waarde,et al.  Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo , 2010, Molecular Cancer.

[4]  R. McLendon,et al.  MRP3: a molecular target for human glioblastoma multiforme immunotherapy. , 2010, BMC Cancer.

[5]  R. McLendon,et al.  Recombinant single‐chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas , 2010, International journal of cancer.

[6]  R. Herbst,et al.  Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Krakstad,et al.  Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics , 2010, Molecular Cancer.

[8]  W. Helfrich,et al.  Review: On TRAIL for malignant glioma therapy? , 2010, Neuropathology and applied neurobiology.

[9]  E. Smit,et al.  Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Fuller.  The WHO Classification of Tumours of the Central Nervous System, 4th edition. , 2009, Archives of pathology & laboratory medicine.

[11]  T. Bijma,et al.  A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability , 2009, Leukemia.

[12]  O. Wiestler,et al.  Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins , 2008, Oncogene.

[13]  A. Ashkenazi.  Targeting the extrinsic apoptosis pathway in cancer. , 2008, Cytokine & growth factor reviews.

[14]  A. Oza,et al.  A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies , 2008, Clinical Cancer Research.

[15]  J. Meixensberger,et al.  Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis , 2007, Clinical Cancer Research.

[16]  R. Pieper,et al.  Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme , 2006, Expert review of anticancer therapy.

[17]  B. Kroesen,et al.  Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR* , 2005, Journal of Biological Chemistry.

[18]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[19]  H. Walczak,et al.  Target cell‐restricted and ‐enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma‐associated antigen EGP2 , 2004, International journal of cancer.

[20]  M. Kool,et al.  Tissue Distribution and Induction of Human Multidrug Resistant Protein 3 , 2002, Laboratory Investigation.

[21]  K. Totpal,et al.  Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. , 2001, The Journal of pharmacology and experimental therapeutics.

[22]  D. Keppler,et al.  Up‐regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver , 2001, Hepatology.

[23]  M. Fukui,et al.  Involvement of the Multidrug Resistance Protein 3 in Drug Sensitivity and Its Expression in Human Glioma , 2001, Japanese journal of cancer research : Gann.

[24]  J. Tschopp,et al.  The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation* , 2000, The Journal of Biological Chemistry.

[25]  R. Strausberg,et al.  Identifying potential tumor markers and antigens by database mining and rapid expression screening. , 2000, Genome research.

[26]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[27]  I. Pastan,et al.  125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  G. Schackert,et al.  Expression ofTRAILand Its Receptors in Human Brain Tumors , 1999 .

[29]  S. Batra,et al.  Pharmacokinetics and biodistribution of genetically engineered antibodies. , 2002, Current opinion in biotechnology.

[30]  R. Kreitman.  Immunotoxins for targeted cancer therapy. , 1998, The AAPS journal.

[31]  S. Srinivasula,et al.  Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL* , 1997, The Journal of Biological Chemistry.

[32]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[33]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[34]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[35]  P F Morrison,et al.  Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  N. Chang.  Induction of Apoptosis in U251 Polymorphic Glioblastoma Cells by Recombinant AntiMRP3(scFv)-sTRAIL Fusion Protein , 2012 .

[37]  B. Kroesen,et al.  Targeted induction of apoptosis for cancer therapy , 2006 .

[38]  A. Evdokiou,et al.  Death to the bad guys: Targeting cancer via Apo2L/TRAIL , 2005, Apoptosis.

[39]  D. Waugh,et al.  Escherichia coli maltose‐binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused , 1999, Protein science : a publication of the Protein Society.

[40]  G. Schackert,et al.  Expression of TRAIL and its receptors in human brain tumors. , 1999, Biochemical and biophysical research communications.

[41]  B. Kroesen,et al.  Simultaneous inhibition of EGFR signaling and enhanced activation of TRAIL-R-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. , 2022 .